Presidio Snaps Up XTL’s Early Hep C Program
This article was originally published in The Pink Sheet Daily
Executive Summary
NS5A inhibitor is valued at $4 million upfront, as much as $104 million more later.
You may also be interested in...
Protease Inhibitors Line Up To Challenge Vertex In HCV
In-class skirmish likely as combo therapy evolves, analyst tells “The Pink Sheet” DAILY.
DOV Out-Licenses Pain Candidate Bicifadine To XTL
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.